Rosetta Genomics Raises $6M in Direct Offering, Regains Nasdaq Compliance with Bid Requirement | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday that it has netted proceeds of about $6 million from a direct offering, and that it has regained compliance on at least one of two Nasdaq listing requirements that it previously failed to meet.

It added that it believes it has regained compliance with the second listing requirement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.